...
首页> 外文期刊>Journal of cataract and refractive surgery >Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification
【24h】

Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification

机译:预防性奈帕芬酸和酮咯酸与安慰剂相比可预防非均匀超声乳化术后黄斑水肿

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To evaluate the efficacy of prophylactic ketorolac 0.5% versus nepafenac 0.1% versus placebo on macular volume 1 month after uneventful phacoemulsification and evaluate the health-related quality-of-life (HRQOL) of topical nonsteroidal antiinflammatory drugs (NSAIDs) in the context of cataract surgery. Setting: Hotel Dieu Hospital, Kingston, Ontario, Canada. Design: Prospective placebo-controlled parallel-assignment double-masked randomized clinical trial. Methods: In this study, patients 18 years or older scheduled for routine phacoemulsification were randomized to a placebo, ketorolac 0.5%, or nepafenac 0.1% and dosed 4 times a day starting 1 day before surgery and continuing for 4 weeks. Spectral-domain macular cube ocular coherence tomography scans measuring central subfield thickness, macular cube volume, and average macular cube thickness were performed at baseline and 1 month postoperatively. The HRQOL metrics were determined with the Comparison of Ophthalmic Medications for Tolerability (COMTOL) questionnaire. Results: Each study group comprised 54 patients. One month postoperatively, although a trend toward significance occurred for nepafenac and ketorolac, analysis of the means of differences showed no statistically significant differences between the 3 study groups (P=.2901). The COMTOL analysis found no difference in tolerability, compliance, side-effect frequency and bother, and effects on HRQOL between ketorolac and nepafenac compared with the placebo. Conclusions: One month after uneventful phacoemulsification, there was no difference in macular volume between the placebo, ketorolac, and nepafenac. Ketorolac and nepafenac were well tolerated with minimal side-effect profiles. Thus, for patients without risk factors having routine surgery, prophylactic topical NSAIDs are not recommended. Financial Disclosure: No author has a financial or proprietary interest in any material or method mentioned.
机译:目的:评估非超声乳化术1个月后预防性酮咯酸0.5%相对于奈帕芬酸0.1%相对于安慰剂对黄斑体积的功效,并评估局部用非甾体类抗炎药(NSAIDs)的健康相关生活质量(HRQOL)白内障手术。地点:加拿大安大略省金斯顿Dieu医院酒店。设计:前瞻性安慰剂对照的平行分配双掩蔽随机临床试验。方法:在本研究中,计划进行常规超声乳化术的18岁或18岁以上患者被随机分配至安慰剂,酮咯酸0.5%或尼帕芬酸0.1%,并在手术前1天开始每天给药4次,并持续4周。在基线和术后1个月进行光谱域黄斑立方眼相干断层扫描,以测量中心亚视野厚度,黄斑立方体积和平均黄斑立方厚度。 HRQOL指标是使用“眼科药物耐受性比较”(COMTOL)调查表确定的。结果:每个研究组包括54例患者。术后一个月,尽管尼帕芬酸和酮咯酸出现了显着趋势,但对差异均值的分析显示,三个研究组之间无统计学差异(P = .2901)。 COMTOL分析发现,与安慰剂相比,酮咯酸和奈帕芬酸之间的耐受性,依从性,副作用频率和困扰以及对HRQOL的影响无差异。结论:正常超声乳化术后1个月,安慰剂,酮咯酸和奈帕芬酸之间的黄斑体积无差异。 Ketorolac和nepafenac的耐受性良好,副作用最小。因此,对于没有危险因素进行常规手术的患者,不建议使用预防性局部NSAID。财务披露:没有任何作者对所提及的任何材料或方法有财务或专有利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号